Physician profile
Kourous Attaran Rezaei
NPI 1366428070
$126,114.96
in general payments reported to CMS, 2019-2025
10 companies · $29K in 2025
The $29K reported for 2025 was more than what 95% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $3,686 · 2021: $24K · 2022: $3,154 · 2023: $11K · 2024: $21K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Travel and Lodging: $14K · Acquisitions: $9,978 · Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $36,455.00 |
| Travel and Lodging | $13,847.06 |
| Acquisitions | $9,978.00 |
| Food and Beverage | $690.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $85,107.18 | 2019-2025 | Constellation, Unity |
| Alcon Research LLC | $23,225.75 | 2019-2025 | Constellation |
| US Retina LLC | $17,136.37 | 2019-2023 | |
| Genentech USA, INC. | $287.26 | 2020-2025 | Susvimo |
| Bausch & Lomb Americas INC. | $149.53 | 2024 | Vyzulta |
| Regeneron Healthcare Solutions, INC. | $93.01 | 2019-2024 | Eylea Hd |
| Abbvie INC. | $41.88 | 2022-2025 | |
| Coherus Oncology, INC. | $26.52 | 2023 | |
| Novartis Pharmaceuticals Corporation | $25.31 | 2019 | |
| Apellis Pharmaceuticals, INC. | $22.15 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$78,833.66 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kourous Rezaei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.